Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?

In the phase I/II BRUIN trial, responses with pirtobrutinib occurred across prespecified subgroups regardless of demographics, number of prior lines of therapy, or prior therapy. Responses were seen in patients with blastoid and pleomorphic histology, regardless of the number of prior lines of thera...

Interestingly, there were no specific or identifiable characteristics that helped predict patients who are responders from non-responders to pirtobrutinib. There was no difference in ORR by prior exposure to stem cell transplant, CAR-T, presence of p53 mutation, histology, or ki67%. Not surprisingly...